Navigation Links
Drug May Extend Life When Breast Cancer Spreads
Date:5/26/2009

Study funded by pharmaceutical company finds benefits in Abraxane,,,,

TUESDAY, May 26 (HealthDay News) -- A new study affirms that the chemotherapy drug Abraxane is more effective, with less troublesome side effects, than the current drug of choice for metastatic breast cancer.

When compared with Taxotere, Abraxane extended the time before a recurrence by almost seven months, effectively doubling survival. Both are members of a class of drugs known as taxanes.

The study, which was a phase 2 trial, was funded by Abraxis BioScience, which makes Abraxane. The findings are reported in the May 26 issue of the Journal of Clinical Oncology.

"This data, which has been presented at national meetings, reaffirms that Abraxane is a very active drug, is well-tolerated and appears to have a greater anti-tumor effect than what you would see with what had been presumed to be the most active drug," said Dr. William Gradishar, director of breast medical oncology at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. "This probably will encourage people to either use or try Abraxane, as opposed to other taxanes."

Another expert agreed.

"This is a major advance. It's a very well-tolerated drug and has low toxicity. We've used this regimen for a number of years now and it's very good," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge. "We're now beginning to realize that many drugs given more frequently at lower doses is not only less toxic but has less side effects. It still doesn't cure people but it's a kinder, gentler way of delivering drugs, although it is more expensive."

Abraxane (nab-paclitaxel) was approved for use in the United States in 2005.

"There has been sort of a preconceived notion that Taxotere is the most potent anti-cancer therapy for metastatic breast cancer, certainly among taxanes," Gradishar said. "That's why this comparison was being made." Gradishar, who was the lead author for the study, is also a consultant to Abraxis BioScience.

The chemotherapy drugs docetaxel, marketed as Taxotere, and paclitaxel are considered the gold standard for treating breast cancer that has spread to other parts of the body.

Abraxane, which is a variant of paclitaxel, uses a different, solvent-free "delivery" system to get the drug into the body.

For the study, 302 women who had not previously been treated for advanced breast cancer were randomized into one of four treatment arms. Three of the four groups were given Abraxane, administered one of three ways: every three weeks, weekly at a lower dose for three weeks with the fourth week off, or weekly at a higher dose for three weeks with the fourth week off. The fourth group was given Taxotere every three weeks at the standard dose.

Abraxane was found to be generally superior to Taxotere in response rates, but the most striking results were seen when the drug was given on a weekly schedule with the fourth week off.

"The anti-tumor effect was greater, and this is how the drug is very commonly used in practice today, although it's approved as an every-three-week drug," Gradishar said. "That also translated into a longer time until the disease progressed."

Abraxane also had fewer side effects than Taxotere, the researchers found. All-in-all, the authors stated, the results suggest that Abraxane may be a preferable first choice for treating this group of patients.

A phase 3 trial comparing the same set of drug regimens is being planned.

One expert noted that the weekly regimen appeared the best.

"This is slightly disappointing in that the every-three-weeks schedule was not as good. That's more convenient for patients," said Dr. Jennifer Eng-Wong, an assistant professor of oncology at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "But it doesn't look like it's the right way to go."

Other reports in the Journal of Clinical Oncology include:

  • A study from National Cancer Institute investigators that found that people with early-stage breast cancer who have high levels of C-reactive protein and serum amyloid A -- both markers of inflammation -- were two to three times more likely to die of their disease or see their cancer return than people with lower levels of the proteins.
  • New guidelines from the American Society of Clinical Oncology stating that women at a heightened risk of developing breast cancer might benefit from the drug Evista (raloxifene) in addition to tamoxifen. Previous guidelines recommended only tamoxifen.

More information

The U.S. National Cancer Institute has more on breast cancer.



SOURCES: William Gradishar, M.D., director, breast medical oncology, Robert H. Lurie Comprehensive Cancer Center, and professor, medicine, Feinberg School of Medicine, Northwestern University, Chicago; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Jennifer Eng-Wong, M.D., assistant professor, oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; May 26, 2009, Journal of Clinical Oncology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Weight-Loss Surgeries Extend Lives
2. Siemens Extends Tender Offer for Acquisition of Dade Behring
3. Global Med Technologies(R) Extends Its Worldwide Outreach
4. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Cancer control in Europe works; now it is time to extend it to poorer countries
7. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
8. NIH/NCI renews and extends nationwide license for Genomatix software and databases
9. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
10. Summer Temperatures Linger, Extend Threat of Parasites
11. Pelosi Statement on House Vote to Extend Family and Medical Leave for Military Families
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Extend Life When Breast Cancer Spreads
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/27/2016)... Wis. (PRWEB) , ... May 27, 2016 , ... ... $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... accepted her award on May 18 at the university’s Student Leadership Awards ceremony. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... ... 2016 , ... W.S. Badger Co. Inc ., the maker of certified ... Work Works Award for its use of effective workplace strategies to increase business and ... administered by the Families and Work Institute (FWI) and the Society for Human Resource ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry leader ... its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May ... of America’s healthcare providers. , The conference was highlighted by the announcement of ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 MedDay, ... disorders, announces that an oral presentation entitled "High doses of ... MS-SPI trial" will be given by Professor Ayman Tourbah ... 2nd Congress of the European Academy of Neurology (EAN) in ... and related disorders 3" will take place on Sunday, 29 ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
Breaking Medicine Technology: